Screener
McKesson MCK Oncology & Multispecialty — Goodwill
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by McKesson in its filing.
Tagged under the XBRL concept us-gaap:Goodwill.
The source filing: McKesson’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 5:29 PM EDT
- Fiscal quarter
- Q1 FY2027
- Calendar quarter
- Q2 2026
- Accession
- 0000927653-26-000234
| (In millions) | North American Pharmaceutical | Oncology & Multispecialty | Prescription Technology Solutions | Medical-Surgical Solutions | Total |
|---|---|---|---|---|---|
| Balance, March 31, 2026 | $2,781 | $3,963 | $2,065 | $2,507 | $11,316 |
| Goodwill acquired | — | 13 | — | — | 13 |
| Disposals | — | (2) | — | — | (2) |
| Foreign currency translation adjustments, net | (26) | — | — | — | (26) |
| Other adjustments (1) | — | (23) | — | — | (23) |
| Balance, June 30, 2026 | $2,755 | $3,951 | $2,065 | $2,507 | $11,278 |
Item 1. Condensed Consolidated Financial Statements.
FAQ
- What is McKesson's oncology & multispecialty — goodwill?
- McKesson (MCK) reported oncology & multispecialty — goodwill of $3.95B in Q2 2026.
- What does oncology & multispecialty — goodwill mean?
- This metric represents the carrying value of goodwill allocated to the Oncology and Multispecialty segment, arising from past business acquisitions. It reflects the premium paid over the fair value of net identifiable assets, representing the segment's long-term strategic value and market position.
Ask your AI about McKesson's oncology & multispecialty — goodwill.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude